Saturday 17 October 2026 Export TFX’s income statement to Excel — free account

Teleflex Incorporated

TFX Healthcare Medical Instruments & Supplies

In the quarter to June 2026, revenue grew 28.9%, EPS fell 17.3%, free cash flow grew 220.1% and total debt rose 47.7%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years.

130.43 2.21 +1.72%

Follow TFX

Alert me

Market cap: $5.4B
P/E: 0.0×
Fwd P/E: 45.3×
Dividend yield: 1.04%
F-score: 5/9
Altman Z: 2.04
Beneish M: −2.21
Dividend safety: 20/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.56%

Capital & Financial Ratios $m

Market Cap 5,430.00

Revenue 2,254.52

Net Income (1,031.68)

Free Cash Flow 168.40

Net Debt 2,507.85

Current Ratio 2.60

Debt/Equity 0.97

P/E ratio 0.00

Fwd P/E 45.30

P/S ratio 2.52

P/B ratio 1.96

Past 5Y EPS Growth —

This Y EPS Growth 3.21%

Next Y EPS Growth 52.02%

Next Y revenue growth 13.81%

Next 5Y EPS Growth 20.16%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.02%

10-year low 10-year high

P/B against its own 10 years 14.89%

10-year low 10-year high

EV/Sales against its own 10 years 5.27%

10-year low 10-year high

EV/FCF against its own 10 years 59.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 1.36

Annual Dividend Yield 1.04%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	1.36	0.34 0.34 0.34
2025	1.36	0.34 0.34 0.34 0.34
2024	1.36	0.34 0.34 0.34 0.34
2023	1.70	0.34 0.34 0.34 0.34 0.34
2022	1.36	0.34 0.34 0.34 0.34
2021	1.36	0.34 0.34 0.34 0.34
2020	1.36	0.34 0.34 0.34 0.34
2019	1.36	0.34 0.34 0.34 0.34
2018	1.36	0.34 0.34 0.34 0.34
2017	1.70	0.34 0.34 0.34 0.34 0.34
2016	1.36	0.34 0.34 0.34 0.34

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	223	248	379	300
Receivables	443	227	346	365
Inventory	626	307	404	352
Other	—	—	—	—
	1,407	1,471	1,938	1,876

	2023	2024	2025	Q'26
Payables	132	98	130	143
ST’ Debt	88	100	100	88
Other	47	59	137	88
	607	649	762	720

Compound Annual Growth %

	10y	5y	3y
Sales	0.97%	(4.72%)	(10.62%)
Cash Flow	(10.81%)	(26.05%)	(34.42%)
Earnings	0.00%	0.00%	0.00%
Book Value	4.51%	(1.30%)	(8.07%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	548	570	—	—	—
’25	414	443	913	223	1,993
’24	738	750	764	—	1,700
’23	711	743	746	—	1,712
’22	642	705	687	758	2,791
’21	634	713	700	762	2,810
’20	631	567	628	711	2,537

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	47	92	—	—	—
’25	28	(37)	198	(92)	97
’24	113	92	231	(134)	302
’23	84	86	202	(166)	206
’22	62	40	143	98	343
’21	111	154	185	202	652
’20	(11)	145	107	196	437

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	28	78	—	—	—
’25	4	(65)	156	(93)	1
’24	74	57	210	(130)	211
’23	63	69	177	(149)	160
’22	49	20	135	59	264
’21	92	137	170	182	581
’20	(31)	126	84	167	346

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.18)	2.28	—	—	—
’25	2.07	2.77	(9.24)	(16.15)	(20.25)
’24	0.32	1.69	2.36	(2.95)	1.48
’23	1.62	2.35	2.90	0.66	7.53
’22	1.63	2.23	2.16	1.66	7.68
’21	1.58	1.76	4.20	2.70	10.23
’20	2.78	0.24	2.46	1.61	7.09

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	125.28	157.80	226.02	244.77	221.27	289.00	182.65	177.63	171.69	102.58	Analyst estimates 2026–2028 Powerpack
	High	188.79	271.23	288.78	376.54	412.99	449.38	356.72	276.43	256.85	185.94
People
People	Employees	12,600	14,400	15,200	14,400	14,000	14,000	15,500	14,500	14,100	15,500
	Revenue/emp, $m	0.15	0.15	0.16	0.18	0.18	0.20	0.18	0.12	0.12	0.13
Income, $m
Income, $m	Revenue	1,868	2,146	2,448	2,595	2,537	2,810	2,791	1,712	1,700	1,993
	Gross margin, %	53.33	54.60	53.21	54.29	52.22	55.15	54.86	60.74	61.04	56.24
	EBT	246	285	220	340	358	559	446	185	26	25
	EBT margin, %	13.15	13.27	8.97	13.10	14.10	19.91	15.98	10.83	1.55	1.23
	Net income	238	153	201	461	335	485	363	356	70	(906)
	Depreciation	128	160	215	218	232	242	235	152	165	182
Per share, $
Per share, $	Revenue	43.12	47.69	53.59	56.18	54.58	60.07	59.51	36.45	36.29	44.66
	Earnings	5.48	3.39	4.39	9.99	7.21	10.38	7.74	7.58	1.49	(20.30)
	Cash flow	9.48	9.47	9.52	9.46	9.40	13.94	7.31	4.39	6.45	2.17
	Capex	(1.23)	(1.58)	(1.77)	(1.91)	(1.95)	(1.53)	(1.69)	(0.99)	(1.93)	(2.13)
	Free cash flow	8.25	7.90	7.75	7.55	7.45	12.41	5.62	3.40	4.51	0.03
	Book value	49.34	54.01	55.59	64.49	71.77	80.27	85.76	94.53	91.34	70.03
	Shares, m	43	45	46	46	46	47	47	47	47	45
Valuation, ×
Valuation, ×	P/E	28.99	75.36	58.88	37.68	57.00	31.68	32.24	33.04	122.74	0.00
	P/S	3.68	5.34	4.82	6.70	7.54	5.47	4.20	6.87	4.90	2.73
	P/B	3.22	4.72	4.65	5.84	5.73	4.09	2.91	2.65	1.95	1.74
	EV/Sales	3.95	6.23	5.56	7.32	8.37	5.97	4.71	7.80	5.73	3.87
	EV/FCF	20.63	37.65	38.42	54.48	61.30	28.89	49.83	83.64	46.08	5,330.95
Cash, $m
Cash, $m	Operating cash flow	411	426	435	437	437	652	343	206	302	97
	Capex	(53)	(71)	(81)	(88)	(91)	(72)	(79)	(46)	(90)	(95)
	Free cash flow	357	355	354	349	346	581	264	160	211	1
Balance, $m
Balance, $m	Working capital	756	645	654	743	882	749	829	801	822	1,176
	Total debt	1,035	2,250	2,159	1,909	2,478	1,850	1,712	1,815	1,656	2,641
	Net debt	491	1,916	1,802	1,608	2,103	1,405	1,419	1,592	1,408	2,263
	Shareholders’ equity	2,138	2,431	2,540	2,979	3,336	3,755	4,022	4,441	4,278	3,125
Returns, %
Returns, %	ROA	6.12	3.03	3.22	7.33	4.98	6.92	5.26	4.93	0.95	(12.90)
	ROIC	7.59	5.35	4.63	5.74	4.86	6.50	5.74	2.63	1.14	1.37
	ROE	11.44	6.68	8.08	16.72	10.62	13.69	9.34	8.42	1.60	(24.47)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 1 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ATR AptarGroup, Inc.	$7.9B	22.2×	21.0×	+6.26% (above 0%: growing)	−18.34% (below 0%: shrinking)	−23.07% (below 0%: shrinking)	35.61%	12.34%	Compare
BLCO Bausch + Lomb Corporation	$6.0B	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+251.85% (above 0%: growing)	62.20%	5.95%	Compare
TFX Teleflex Incorporated	$5.4B	— (loss-making)	45.3×	+28.88% (above 0%: growing)	−17.33% (below 0%: shrinking)	+220.14% (above 0%: growing)	58.16%	12.77%
MMSI Merit Medical Systems, Inc.	$5.4B	36.4×	23.4×	+9.51% (above 0%: growing)	+18.18% (above 0%: growing)	−25.66% (below 0%: shrinking)	51.37%	14.42%	Compare
STVN Stevanato Group S.p.A.	$5.3B	33.8×	27.5×	+10.46% (above 0%: growing)	−25.00% (below 0%: shrinking)	−167.02% (below 0%: shrinking)	28.75%	12.93%	Compare
ICUI ICU Medical, Inc.	$4.2B	136×	49.5×	+0.51% (above 0%: growing)	−46.85% (below 0%: shrinking)	+655.98% (above 0%: growing)	42.61%	7.09%	Compare
NVST Envista Holdings Corporation	$3.8B	38.8×	24.4×	+7.10% (above 0%: growing)	+106.25% (above 0%: growing)	+37.57% (above 0%: growing)	55.72%	10.99%	Compare
PLSE Pulse Biosciences, Inc	$3.3B	— (loss-making)	— (loss-making)	+4,922.22% (above 0%: growing)	n/m	−45.39% (below 0%: shrinking)	37.10%	(5,823.04%)	Compare
WRBY Warby Parker Inc.	$3.0B	334×	122×	+9.81% (above 0%: growing)	n/m	−71.75% (below 0%: shrinking)	57.94%	1.34%	Compare
Median of peers	$4.7B	37.6×	26.0×	+9.30%	−18.34%	−24.36%	46.99%	9.04%

All 55 Medical Instruments & Supplies stocks →

Teleflex Incorporated (TFX) key facts

Concern: Teleflex Incorporated reported a net loss of $905.6 million, or a loss of $20.30 per share, for fiscal 2025.
Teleflex Incorporated (TFX) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, TFX traded at $130.43, a market capitalization of $5.4 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.5× sales.
Teleflex Incorporated pays an annual dividend of $1.36 per share, a yield of 1.04%.
Return on equity was −24.5% and debt-to-equity 0.97.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 2.04 (grey zone) for fiscal 2025.